Isomorphic Labs Announces First AI-Discovered Drug Candidates Entering Clinical Trials, Backed by Google and Nobel Laureate Founder

Today, the AI pharmaceutical unicorn spun off from DeepMindIsomorphic LabsAnnounced with great fanfare, itsBased onAlphaFoldThe first batch of candidate drugs discoveredWillEnter Clinical Trials！

This is a milestone event for the company and the entire biopharmaceutical industry.

To know,The application of AlphaFold is mainly concentrated in the scientific research community., there is still a distance from industrial implementation.

At the end of 2021, DeepMind was established.Isomorphic, the majority of the initial members came from the AlphaFold2 team,Secretly Developing AlphaFold3 and Drug Discovery Platform.

And after years of research and development,IsomorphicTheAIClinical Trials of Auxiliary Drugs Finally Surface

At the same time, it also marks,AIA crucial step for the pharmaceutical industry moving from theory to practice.

BuildAIUniversal Engine Driving Drug Discovery

The company isDeepMindBased onAlphaFold2Derived from the transformation of achievements,DeepMindIsomorphic Labs is the world's topAIOne of the research institutions.

Backed by Google, Isomorphic Labs was founded with ambitious plans:

“UseAIRedefining Drug Discovery”。

The development of traditional drugs takes an average of ten years and costs billions of dollars.And the success rates and methods for development vary across different targets.

As for Isomorphic LabsIn useAICreate a universal drug design engine that can not only be used for a single target or a single drug type, but can also be repeatedly applied to any different disease areas.

This is not just a slogan; the company has gathered the most outstanding talents from all over the world.The most outstanding biologists, AI scientists, chemists, and engineers, as well as the gathering ofScientific expertise, hoping to change the way drugs are discovered.

FounderDemis HassabisNot only the company'sCEO, alsoGoogle DeepMindTheThe person in charge, undertakes the mission of competing with OpenAI.

He also has another identity.——2024Nobel Prize in Chemistry Winner, led by himAlphaFold2The predicted protein structure has reached a level of accuracy close to that of laboratory results, solving a problem that has troubled the scientific community.50Problems in recent years.

The company also attractedDr. Miles CongreveAs the Chief Scientific Officer, he has 25 years of senior experience in drug research and development and is also a key figure in the development of blockbuster breast cancer drugs.Ribociclib (ribociclib)The main inventor.

Now,HassabisHope toAIAccelerate forward in drug research and development.

AlphaFold2Only the design problem of monomeric proteins has been solved, but life lies in constant motion and exchange of information substances.

2024Year5Month,IsomorphicUnitedDeepMindJointly releasedAlphaFold3, can predictThe Structure and Interactions of All Biomolecules, becoming a revolutionary tool for drug development.

Demis HassabisOnceBoldlyPrediction:Perhaps within the next decade or so, we may be able to cure all diseases.

And based onAlphaFoldAs a result of these achievements, the company has garnered support from a number of well-known venture capital firms.

This Year4Month, CompanyAnnounced the acquisition of6Billion US dollarsofHuge AmountFinancing, byThrive CapitalLead investment,GVAndAlphabetCo-investment. This funding will be used to support theirAIDrug design engine, and help them advance internal projects into the clinical stage。

Moreover, the world's top pharmaceutical companies are also collaborating withIsomorphicConduct joint research and development.

2024Year, which is also the releaseAlphaFold3In the same year,IsomorphicWith pharmaceutical companiesNovartisAndEli LillySigned a Major Research Collaboration，Total amount exceeding30Billion US dollars.

As the company advances its drug into clinical trials, it also signifies that the company's platform has entered a new historical stage of development, transitioning from early research to clinical development.

Due toWith its strong background and founding team, Isomorphic Labs is capturing the attention of the entire pharmaceutical industry. Can its R&D and drug advancements truly bring revolutionary changes to the field?

In the future, Zhiyao Bureau will continue to focus onClinical Progress of Isomorphic。